Home   »  TRADE TOPICS  »  Prescription Drugs  »  Special 301 Report

Special 301 Report

Submission to the USTR for the 2011 Special 301 Report
Joint submission by the Forum on Democracy and Trade and the National Legislative Association on Prescription Drug Prices. Highlights the concerns of states that trade policy is seeking to create new international norms for pharmaceutical price negotiations, and argues that this issue is outside the scope of the Special 301 Report.
Formal Submissions and Testimony to USTR for the 2010 Special 301 Report
In February 2010, the Forum on Democracy and Trade, along with other groups representing U.S. state governments submitted comments to USTR for the Special 301 Report. On March 3, state leaders testified at a public hearing about the report.
Letter from VT Governor Douglas to DHHS Secretary Kathleen Sebelius
Gov. Douglas expresses concern over the U.S. Trade Representative's policy of targeting countries that negotiate drug prices in the Special 301 Report. He notes that state governments use the same evidence-based pricing mechanisms when they negotiate drug prices for Medicaid and other programs that supply Americans with pharmaceuticals.
Letter from ME Governor Baldacci to DHHS Secretary Sebelius
Letter written to DHHS Secretary Sebelius describing trade policy that threatens the sustainability of state programs that negotiate drug prices. This was written shortly before the release of the 2010 Special 301 Report.
Trade & Pharmaceutical Policy Update: USTR Continuing to Use Trade Policy to Restrict Drug Pricing Regulations
Action by states is needed to discourage the recent trend of the U.S. Trade Representative using trade agreements and negotiations to develop new international standards restricting the use of the most effective programs to restrain drug prices.

Unless otherwise expressly stated, all original material of whatever nature created by the Forum on Democracy & Trade website is licensed under a Creative Commons License. Privacy Statement | Sitemap